Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for optimizing a process of manufacturing a biologic pharmaceutical. In one aspect, the method comprises repeatedly performing the following: i) selecting a configuration of input settings for manufacturing a batch of a biologic pharmaceutical based on a causal model that measures current causal relationships between input settings and a measure of a quality of batches of the biological pharmaceutical; ii) determining a measure of the quality of a batch of the biological pharmaceutical manufactured using the configuration of input settings; and iii) adjusting, based on the measure of the quality of the batch of the biological pharmaceutical, the causal model.

Abstract: Imidazoquinoline compounds, salts thereof, conjugates thereof, pharmaceutical compositions containing the compounds and conjugates, and methods of use of such compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals.

Abstract: Imidazoquinoline compounds, salts thereof, conjugates thereof, pharmaceutical compositions containing the compounds and conjugates, and methods of use of such compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for selecting settings for a treatment of a patient. In one aspect, the method comprises repeatedly performing the following: i) selecting a configuration of input settings for providing a treatment to a patient based on a causal model that measures current causal relationships between input settings and effects of treatments on the patient; ii) receiving a measure of an effect of the treatment on the patient; and iii) adjusting, based on the measure of the effect of the treatment on the patient, the causal model.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for optimizing a process of manufacturing a biologic pharmaceutical. In one aspect, the method comprises repeatedly performing the following: i) selecting a configuration of input settings for manufacturing a batch of a biologic pharmaceutical based on a causal model that measures current causal relationships between input settings and a measure of a quality of batches of the biological pharmaceutical; ii) determining a measure of the quality of a batch of the biological pharmaceutical manufactured using the configuration of input settings; and iii) adjusting, based on the measure of the quality of the batch of the biological pharmaceutical, the causal model.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for designing a clinical trial. In one aspect, the method comprises repeatedly performing the following: i) selecting, from a population of patients, patients for being treated with the treatment using a configuration of input settings, wherein the configuration is selected based on a causal model that measures current causal relationships between input settings and a measure of success of the clinical trial; ii) determining the measure of success of the clinical trial for which patients were selected using the certain configuration of input settings; and iii) adjusting, based on the measure of success of the clinical trial, the causal model.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for controlling operations of one or more healthcare facilities. In one aspect, the method comprises repeatedly performing the following: i) selecting a configuration of input settings for controlling operations of the healthcare facilities based on a causal model that measures current causal relationships between input settings and a measure of success of operations at the healthcare facilities; ii) receiving a measure of success of the operation of the healthcare facilities while controlled using the configuration of input settings; and iii) adjusting, based on the measure of success of the operation of the healthcare facilities while controlled using the configuration of input settings, the causal model.

Abstract: The present invention provides method for treating a patient with cutaneous T cell lymphoma (CTCL). Generally, the methods include administering to the patient an IRM compound in an amount effective to ameliorate at least one symptom or clinical sign of CTCL. In some embodiments, the methods also include administering to the patient a priming dose of a Type I interferon. In another aspect, the invention provides methods of increasing a cell-mediated immune response of a cell population that includes cells affected by cutaneous T cell lymphoma. Generally, the methods include contacting the cell population with an IRM compound in an amount effective to increase at least one cell-mediated immune activity of the cell population. In some embodiments, the methods include contacting the cell population with a priming dose of a Type I interferon.

Abstract: Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.

Abstract: Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.

Abstract: The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.

Abstract: Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.

Abstract: The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.

Abstract: The present invention provides method for treating a patient with cutaneous T cell lymphoma (CTCL). Generally, the methods include administering to the patient an IRM compound in an amount effective to ameliorate at least one symptom or clinical sign of CTCL. In some embodiments, the methods also include administering to the patient a priming dose of a Type I interferon. In another aspect, the invention provides methods of increasing a cell-mediated immune response of a cell population that includes cells affected by cutaneous T cell lymphoma. Generally, the methods include contacting the cell population with an IRM compound in an amount effective to increase at least one cell-mediated immune activity of the cell population. In some embodiments, the methods include contacting the cell population with a priming dose of a Type I interferon.

Abstract: The disclosure provides methods for the treatment and prevention of periodontal disease. In preferred embodiments, the invention provides for local treatment of periodontal tissues with a pharmaceutical composition including an immune response modifier (IRM) selected from the group of immune response modifiers comprising imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphtyridine amines, oxazoloquinoline amines, thiazoloquinoline amines and 1,2-bridged imidazopyridine amines.

Abstract: Dye labeled imidazonaphthyridine, imidazopyridine and imidazoquinoline compounds having immune response modulating activity are disclosed. The compounds arc useful, inter alia, for determining the binding and/or receptor sites of the molecules.

Abstract: Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.

Abstract: Immune response modifier compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines—are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokin induction and eosinophilia, as well as enhance TH1 immune response.

Abstract: The disclosure provides methods for the treatment and prevention of periodontal disease. In preferred embodiments, the invention provides for local treatment of periodontal tissues with a pharmaceutical composition including an immune response modifier (IRM) selected from the group of immune response modifiers comprising imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphtyridine amines, oxazoloquinoline amines, thiazoloquinoline amines and 1,2-bridged imidazopyridine amines.

Abstract: Immune response modifier compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines—are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.